解析嵌合抗原受体T细胞疗法（CAR-T）后输血的预后作用 - Suppr

Suppr

超能文献

Navigating the prognostic role of transfusions after CAR-T.

作者信息

Alhomoud Mohammad, Rejeski Kai

机构信息

Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY.

Department of Medicine III - Hematology/Oncology, LMU University Hospital, LMU Munich, Munich, Germany.

出版信息

Blood Adv. 2024 Mar 26;8(6):1570-1572. doi: 10.1182/bloodadvances.2024012583.

DOI:10.1182/bloodadvances.2024012583

PMID:38530306

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10982968/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a11/10982968/78ea54a358fc/BLOODA_ADV-2024-012583-C-gr1.jpg

相似文献

Navigating the prognostic role of transfusions after CAR-T.解析嵌合抗原受体T细胞疗法（CAR-T）后输血的预后作用

Blood Adv. 2024 Mar 26;8(6):1570-1572. doi: 10.1182/bloodadvances.2024012583.

Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells.嵌合抗原受体 T 细胞过继免疫治疗后原发性和继发性中枢神经系统淋巴瘤的神经毒性及处理。

Neuro Oncol. 2023 Dec 8;25(12):2239-2249. doi: 10.1093/neuonc/noad118.

Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.CD22/CD19 嵌合抗原受体 T 细胞疗法治疗累及胃肠道的复发/难治性侵袭性 B 细胞淋巴瘤患者的疗效和毒性。

Cytotherapy. 2020 Mar;22(3):166-171. doi: 10.1016/j.jcyt.2020.01.008. Epub 2020 Feb 13.

Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature.嵌合抗原受体 T 细胞（CAR T）治疗难治/复发 B 细胞淋巴瘤后发生的继发性髓系肿瘤：病例系列及文献复习。

Front Immunol. 2023 Jan 13;13:1063986. doi: 10.3389/fimmu.2022.1063986. eCollection 2022.

Unanswered questions following reports of secondary malignancies after CAR-T cell therapy.嵌合抗原受体T细胞（CAR-T）疗法后出现继发性恶性肿瘤报告后的未解问题。

Nat Med. 2024 Feb;30(2):338-341. doi: 10.1038/s41591-023-02767-w.

Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas.嵌合抗原受体修饰 T 细胞疗法治疗 B 细胞非霍奇金淋巴瘤。

Am J Hematol. 2019 May;94(S1):S18-S23. doi: 10.1002/ajh.25403. Epub 2019 Jan 24.

Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.第四代抗 CD19 嵌合抗原受体 T 细胞治疗复发/难治性 B 细胞非霍奇金淋巴瘤的 I 期临床试验。

Front Immunol. 2020 Nov 27;11:564099. doi: 10.3389/fimmu.2020.564099. eCollection 2020.

Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.嵌合抗原受体修饰 T 细胞治疗淋巴瘤。

Curr Oncol Rep. 2019 Mar 27;21(5):38. doi: 10.1007/s11912-019-0789-z.

4SCAR2.0: a multi-CAR-T therapy regimen for the treatment of relapsed/refractory B cell lymphomas.4SCAR2.0：一种用于治疗复发/难治性B细胞淋巴瘤的多嵌合抗原受体T细胞（multi-CAR-T）治疗方案。

Blood Cancer J. 2021 Mar 17;11(3):59. doi: 10.1038/s41408-021-00455-x.

Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.嵌合抗原受体 T 细胞疗法治疗侵袭性 B 细胞非霍奇金淋巴瘤：疗效、毒性和比较嵌合抗原受体产品。

Expert Opin Biol Ther. 2019 Nov;19(11):1157-1164. doi: 10.1080/14712598.2019.1644316. Epub 2019 Jul 25.

本文引用的文献

Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome (a DESCAR-T study).嵌合抗原受体 T 细胞（CAR-T）疗法治疗大 B 细胞淋巴瘤后的输血需求：预测因素和结果（DESCAR-T 研究）。

Blood Adv. 2024 Mar 26;8(6):1573-1585. doi: 10.1182/bloodadvances.2023011727.

Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality.应用 CAR-T 后 EHA/EBMT 分级评估 ICAHT：感染和死亡率的比较发生率和相关性。

Blood Adv. 2024 Apr 23;8(8):1857-1868. doi: 10.1182/bloodadvances.2023011767.

Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion.CD19 CAR-T 治疗后严重的血液毒性与抑制性免疫失调和有限的 CAR-T 扩增有关。

Sci Adv. 2023 Sep 22;9(38):eadg3919. doi: 10.1126/sciadv.adg3919.

Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry.嵌合抗原受体 T 细胞疗法治疗大 B 细胞淋巴瘤后的非复发死亡率：来自 DESCAR-T 登记处的 LYSA 研究。

Blood Adv. 2023 Nov 14;7(21):6589-6598. doi: 10.1182/bloodadvances.2023010624.

Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells.CD19 CAR T 细胞治疗后细胞减少症持续时间长与克隆性扩增 IFNγ 表达 CD8 T 细胞骨髓浸润有关。

Cell Rep Med. 2023 Aug 15;4(8):101158. doi: 10.1016/j.xcrm.2023.101158.

Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations.免疫效应细胞相关血液学毒性：EHA/EBMT 共识分级和最佳实践建议。

Blood. 2023 Sep 7;142(10):865-877. doi: 10.1182/blood.2023020578.

Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy.严重细胞因子释放综合征与 CD19 CAR T 细胞治疗后的血液学毒性有关。

Blood Adv. 2022 Apr 12;6(7):2055-2068. doi: 10.1182/bloodadvances.2020004142.

CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.嵌合抗原受体 T 细胞相关血液学毒性：复发/难治性大 B 细胞淋巴瘤中嵌合抗原受体 T 细胞相关血液学毒性的模型。

Blood. 2021 Dec 16;138(24):2499-2513. doi: 10.1182/blood.2020010543.

Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies.接受嵌合抗原受体T细胞疗法治疗血液系统恶性肿瘤患者的造血恢复情况。

Blood Adv. 2020 Aug 11;4(15):3776-3787. doi: 10.1182/bloodadvances.2020002509.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验